Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.78 |
| ▸ | AOC3 | Q16853 | 17/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16048406 | 0.88 | KCNH2 (0.78) | KCNH2AOC3 | |
| SCHEMBL16048114 | 0.88 | KCNH2 (1.00) | KCNH2AOC3 | |
| SCHEMBL30026179 | 0.88 | KCNH2 (0.78) | KCNH2AOC3 | |
| SCHEMBL30026427 | 0.88 | KCNH2 (1.00) | KCNH2AOC3 | |
| SCHEMBL18211848 | 0.86 | KCNH2 (0.75) | KCNH2AOC3 | |
| SCHEMBL30026073 | 0.86 | KCNH2 (0.75) | KCNH2AOC3 | |
| SCHEMBL16048548 | 0.86 | KCNH2 (0.75) | KCNH2AOC3 | |
| SCHEMBL16053770 | 0.85 | AOC3 (0.78) | KCNH2AOC3 | |
| Hydrochloric Acid SCHEMBL16048739 | 0.85 | AOC3 (0.77) | KCNH2AOC3 | |
| SCHEMBL20924524 | 0.84 | KCNH2 (0.79) | KCNH2AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190728-A1 | NEW THERAPEUTIC USES OF COMPOUNDS | PROXIMAGEN LLC (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190728-A1 | NEW THERAPEUTIC USES OF COMPOUNDS | ACE2, TMPRSS2, IL1B | KCNH2 800/4885AOC3 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.